Group 1 pulmonary hypertension or pulmonary arterial hypertension (PAH) is a rare disease characterized by proliferation and occlusion of small pulmonary arterioles, leading to progressive elevation of pulmonary artery pressure and pulmonary vascular resistance, and right ventricular failure. Historically, it has been associated with a high mortality rate, although, over the last decade, treatment has improved survival. PAH includes idiopathic PAH (IPAH), heritable PAH (HPAH), and PAH associated with certain medical conditions. The aetiology of PAH is heterogeneous, and genetics play an important role in some cases. Mutations in BMPR2, encoding bone morphogenetic protein receptor 2, a member of the transforming growth factor- superfamily of receptors, have been identified in 70% of cases of HPAH, and in 10-40% of cases of IPAH. Other genetic causes of PAH include mutations in the genes encoding activin receptor-like type 1, endoglin, SMAD9, caveolin 1, and potassium two-pore-domain channel subfamily K member 3. Mutations in the gene encoding T-box 4 have been identified in 10-30% of paediatric PAH patients, but rarely in adults with PAH. PAH in children is much more heterogeneous than in adults, and can be associated with several genetic syndromes, congenital heart disease, pulmonary disease, and vascular disease. In addition to rare mutations as a monogenic cause of HPAH, common variants in the gene encoding cerebellin 2 increase the risk of PAH by approximately two-fold. A PAH panel of genes is available for clinical testing, and should be considered for use in clinical management, especially for patients with a family history of PAH.
Introduction
According to the World Health Organization clinical classification, pulmonary hypertension falls into five groups: pulmonary arterial hypertension (PAH) (Group 1); pulmonary hypertension due to left heart disease (Group 2); pulmonary hypertension due to chronic lung disease and/or hypoxia (Group 3); chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary hypertension due to unclear multifactorial mechanisms (Group 5).
Pathologically, PAH is characterized by excessive pulmonary vasoconstriction, abnormal vascular remodelling (including medial hypertrophy, intimal fibrosis, and adventitial proliferation), and obliteration of small pulmonary arterioles, leading to progressive elevation of pulmonary artery pressure, which, in turn, increases afterload of the right ventricle [1] (Figure 1 ). In response to vascular stress, the effects of genetic risk factors, such as mutations in the gene encoding bone morphogenetic protein (BMP) receptor 2 (BMPR2), will interact with those of other signalling molecules (kinases and growth factors). There is hypertrophy of smooth muscle cells, deposition of extracellular matrix, proliferation of endothelial cells, propagation of adventitial fibroblast cells, and remodelling of small pulmonary arteries. Despite recent improvements in management, PAH remains a devastating disease. The pathogenesis of PAH is complex and incompletely understood, but includes both genetic and environmental factors that alter vascular structure and function [2] . Understanding the genetic aetiology of PAH should facilitate better diagnosis and the development of novel therapies in the future. them proliferation, migration, differentiation, apoptosis, and extracellular matrix secretion and deposition. Multiple studies have identified BMPR2 mutations in ∼70% of HPAH cases and in ∼10-40% of idiopathic (IPAH) cases [5] [6] [7] [8] . To date, 390 different BMPR2 mutations have been identified (www.hgmd.cf.ac.uk). These are all loss-of-function mutations, and include nonsense, missense, splicing and frameshift mutations, and deletions or rearrangements affecting one or more exons or the entire BMPR2 gene [9] . It is suggested that nonsense or frameshift mutations cause truncation of the protein and lead to nonsense-mediated decay, whereas missense mutations cause retention of the mutant protein in the endoplasmic reticulum or plasma membrane [10] . BMPR2 mutations occur in ∼20% of adult IPAH cases (Table 1) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Although there is some variability, the average penetrance of BMPR2 mutations is only ∼20%, and a 'second hit' is proposed to be a modulator of disease progression [23, 24] . When lymphocyte-derived human cell lines were used to examine BMPR2 expression, unaffected mutation carriers were shown to have higher levels of wild-type BMPR2 transcripts than affected patients [25] , suggesting that the penetrance of the disease is regulated by the level of expression of the normal BMPR2 allele. These authors also suggested that there is an oestrogen receptor-α-binding site at the BMPR2 promoter, and that BMPR2 expression is reduced in lymphocytes from female patients as compared with those from male patients [26] .
Additional genes related to TGF-β superfamily receptor signalling have been identified as rare causes of PAH; these include the genes encoding activin receptor-like type 1 (ACVRL1), endoglin (ENG), SMAD8 (also known as SMAD9), and SMAD4 [27] [28] [29] [30] [31] [32] [33] [34] (Figure 2 ). The TGF-β family is involved in the regulation of multiple cellular functions and homeostasis, including proliferation, differentiation, apoptosis, and endothelial-mesenchymal transition [35] . TGF-β plays an important role in the respiratory system [36] . The TGF-β-ACVRL1-ENG signalling pathway activates or phosphorylates SMAD1/5/8 and SMAD2/3 through receptors such as BMPR2, and induces the expression of growth factors such as fibroblast growth factor (FGF) 2 and platelet-derived growth factor B [37] . TGF-β regulates the synthesis of platelet-derived growth factors through the non-canonical pathway (C-terminal Src kinase or mitogen-activated protein kinase) in endothelial cells, which can stimulate the growth of vascular smooth muscle cells [38] .
Hereditary haemorrhagic telangiectasia (HHT) genes
HHT is a rare autosomal dominantly inherited disease characterized by telangiectases and arteriovenous malformations (AVMs), including pulmonary AVMs, with variable clinical presentations due to different locations of the lesion. Mutations in ENG or ACVRL1 are present in 80-85% of HHT patients, whereas SMAD4 mutations are present in 1-2% of HHT patients [39, 40] . SMAD4 is a 'co-SMAD' that forms a complex with receptor-activated SMADs (SMAD2/3 or SMAD1/5/8).
Mutations in the gene encoding growth differentiation factor 2 (GDF2) (previously known as BMP9) is a rare genetic cause of HHT [41] ; one study identified three heterozygous missense mutations in GDF2/BMP9 in 1.6% (3/191) of HHT patients [42] , but heterozygous mutations in GDF2/BMP9 have not been reported in HHT-PAH or isolated PAH. Recently, however, a homozygous GDF2/BMP9 nonsense mutation, i.e. c.C76T;p.Gln26Ter, was identified in a child with isolated PAH [43] . The parents were heterozygous for the mutation but were phenotypically normal. It is estimated that 30% of HHT patients have pulmonary AVMs, and a small percentage (<1%) of HHT patients have PAH [44] . Among this small proportion of patients with HHT-PAH, some have PAH that is clinically and histopathologically indistinguishable from other heritable forms of PAH, whereas others have PAH associated with pulmonary arteriovenous fistulas [45] . The underlying causative factor in these patients is typically, mutation of ACVRL1. Up to 20% (16/83) of all detected mutations in ACVRL1 are associated with the development of PAH, and, of these 16 mutations, 81% are repeatedly observed to be associated with PAH [46, 47] . In rare instances (n = 5), mutations of ACVRL1 cause PAH without HHT [48, 49] . PAH genes and signalling pathways. BMP ligands, such as BMP9, bind to BMPR2. Upon ligand binding, BMPR2 phosphorylates BMPR1, including ALK1, ALK2, ALK3, or ALK6 (ACVRL1, ACVR2, BMPR1A, or BMPR1B respectively). The ligand-receptor complex phosphorylates SMAD1/5/8 and subsequently phosphorylates SMAD4. The phosphorylated SMADs translocate to the nucleus, and regulate the expression of target genes. TGF-β ligands, such as ENG, bind TGFβR2 to phosphorylate TGFβRI, including ALK1 (ACVRL1) and ALK5 (TGFBR1). The complex phosphorylates SMAD2/3, which phosphorylates SMAD4 and translocates to the nucleus. CAV1 interacts with BMPR2 to prevent vascular proliferation. BMPR2 phosphorylates SRC, which regulates cell proliferation or regulates CAV1 to activate phosphoinositide 3-kinase (PI3K)/AKT activity. KCNK3 encodes a two-pore potassium channel, and regulates membrane potential and vascular tone. TBX4 regulates FGF10, which binds to FGF receptor 2 (FGFR2) to regulate development in the lung.
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Caveolin 1 (CAV1)
Mutations in CAV1 are rare causes of HPAH and IPAH [50] . CAV1 encodes a membrane protein that is enriched in cell surface caveolae and plays an important role in mediating TGF-β, G-protein and nitric oxide signalling in PAH. CAV1 is expressed ubiquitously, but shows high expression in adipocytes, endothelial cells, and fibroblasts [51] . Homozygous or heterozygous CAV1 mutations have been identified in lipodystrophy or partial lipodystrophy patients [52, 53] . Recently, heterozygous CAV1 mutations were found in patients with isolated PAH or PAH associated with lipodystrophy [51, 54, 55] . The mechanisms of CAV1 mutation in PAH have been extensively studied. In mice, Cav1 is expressed in epithelial and endothelial cells of the septum, which is located between the alveolar space and the blood capillaries in the lung [56] . In humans, CAV1 is located in the endothelium of pulmonary arteries [50] . BMPR2 localizes to caveolae and directly interacts with CAV1 in various cell types, including vascular smooth muscle cells [57, 58] . Other studies have suggested that BMPR2 signalling through SRC regulates CAV1 trafficking in PAH [59] (Figure 2 ).
PAH due to mutations in the gene encoding potassium two-pore-domain channel subfamily K member 3 (KCNK3) KCNK3 , also known as TASK-1, encodes an outwardly rectifying K + channel that is sensitive to changes in extracellular pH. Genetic and electrophysiological studies suggest that KCNK3 mutation is a rare genetic cause of PAH [60] . K + channels constitute the largest and most diverse family of ion channels. According
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to their structure and composition, K + channels are classified into three main groups: voltage-gated (six transmembrane domains or 6TM), inward rectifiers (2TM) and two-pore-domain (4TM) channels [61, 62] . Two-pore-domain channels (K 2P ) are the most recently discovered K + channels. KCNK3, also called TASK-1 or K (2P) 3.1, belongs to this family of K + channels, which are characterized by four transmembrane domains and two pore domains per subunit. Abundant expression of Kcnk3 has been described in rat, rabbit and human pulmonary artery smooth muscle cells (PASMCs). The function of this channel is to conduct leak K + current, maintain the resting membrane potential, and regulate the vascular tone of the pulmonary artery. Activation of the K + channel causes K + efflux, membrane hyperpolarization, and vasodilatation [63] [64] [65] [66] . Besides KCNK3, single-nucleotide polymorphisms in the gene encoding potassium voltage-gated channel subfamily A member 5 (KCNA5), another gene in the K + channel family, have been reported in PAH patients. It is suggested that KCNA5 mutation is a genetic risk factor for the disease, and that KCNA5 has roles in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis [67, 68] .
Paediatric PAH
The prevalence of PAH in children is estimated to be ∼2.2 cases per million, an order of magnitude lower than the estimated prevalence of 15-50 cases per million in adults [69] . Paediatric PAH includes IPAH, HPAH, and PAH associated with congenital heart disease (CHD) and with abnormal lung development.
The genetics of PAH in children have not been extensively studied, but the data suggest that PAH in children may have a different genetic aetiology from that in adults. The paediatric studies have been limited in sample size, and additional larger studies need to be performed. One study identified no BMPR2 mutations in 13 children with IPAH [70] . In a cohort of 57 paediatric PAH patients, 18 BMPR2 and seven ACVRL1 mutation carriers were identified [71] . A study of PAH associated with CHD demonstrated that 22% of children had ACVRL1, ENG or BMPR2 mutations [8] . In a mixed cohort of 40 childhood PAH cases, including 29 IPAH/HPAH and 11 PAH-CHD cases, six BMPR2, two ACVRL1 and two ENG mutations were identified [72] . The differences in genetic results in different paediatric PAH studies are probably due to a combination of small sample sizes, different genetic backgrounds, and different selection criteria, including whether the PAH was associated with other diseases. BMPR2 mutation-positive children appeared to be less likely to respond to acute vasodilators than mutation-negative children [17] .
T-box 4 (TBX4) is a transcription factor in the T-box gene family, and is expressed in the atrium of the heart, the limbs, and the mesenchyme of the lungs and trachea. Jointly with T-box 5, TBX4 has been shown to interact with FGF10 during lung growth and branching [73] . Heterozygous loss-of-function mutations in TBX4 have been previously reported to cause small patella syndrome (SPS) (MIM# 147891) [74] , and heterozygous microdeletions of 17q23.2 encompassing TBX4 were identified in eight patients with developmental delay, limb abnormalities, and CHD, and in one with pulmonary hypertension [75, 76] . One missense and two frameshift variants in TBX4 were identified in six of 20 (30%) paediatric PAH patients [21] , and two missense variants in TBX4 were identified in two of 49 adult PAH patients (4.1%), suggesting a higher frequency of TBX4 mutations in paediatric PAH. Although it had not initially been clinically noted, some of the patients and the asymptomatic parents carrying TBX4 mutations were later assessed for skeletal signs of SPS; in all five available probands and two carrier parents there was radiological evidence of skeletal malformations [21] . In a cohort of 165 adult-onset PAH patients, only one possible mutation (non-frameshift insertion c.310_312 ins AAG, p.L103_V104 ins E) in TBX4 was identified [22] . Rarely, TBX4 mutations have been associated with abnormal lung development, such as acinar dysplasia of the lungs [77] . Table 2 shows a summary of paediatric PAH genetic studies [16, 17, 21, [70] [71] [72] [78] [79] [80] .
Other genes are likely to play an important role in childhood PAH. Two novel missense mutations in BMPR1B were identified in paediatric IPAH patients [81] . These two variants are located in highly conserved BMPR1B protein regions. Functional studies showed that BMPR1B mutant protein increased the phosphorylation of SMAD8. BMPR1B (also known as ALK6) is one of the BMP type I receptors, which interact with BMP type II receptors and mediate BMP signalling. BMPR1B expression was significantly increased in PASMCs isolated from BMPR2-negative PAH patients, whereas BMPR1B transcripts were hardly detectable in control PASMCs [82] .
Two novel missense mutations (G840E and T900P) in NOTCH3 were identified in two PAH patients. These variants are located in highly conserved NOTCH3 protein regions. Functional studies indicated that these mutations increased cell proliferation and viability [83] , suggesting a possible gain of function. As the receptor for JAGGED1, NOTCH3 is involved in vascular homeostasis and PAH [84] . Evidence suggests that TGF-β1 regulates NOTCH3, indicating that NOTCH3 is in the TGF-β signalling network [85] .
Genetics and environmental factors interact in PAH
The genetics of PAH across multiple genes are characterized by a female predominance and incomplete penetrance of dominantly inherited mutations. The age of onset can be modified by a complex interplay of multiple mutations. One BMPR2 mutation carrier has been shown to have a loss of chromosome 13 in the Genetics of pulmonary arterial hypertension 277 pulmonary vasculature, associated with loss of SMAD9 [23] . Some patients have been found to carry multiple variants in PAH risk genes [86] . Differences in BMPR2 expression or isoform ratios may provide an explanation for the reduced penetrance among BMPR2 mutation carriers [87] . The onset of PAH can be modified by association with other diseases or exposures. Heterozygous BMPR2 sequence variants have been identified in a small subset of patients with PAH associated with exposure to fenfluramine [13, 88] , CHD [16] , and veno-occlusive disease [89, 90] , raising the possibility that these factors represent triggers in the setting of inherited susceptibility. In contrast, BMPR2 mutations have not been identified in modestly sized series of PAH associated with scleroderma-spectrum disease, human immunodeficiency virus [91, 92] , Down syndrome [93] , neurofibromatosis 1 [94] , Gaucher disease [95] , or autoimmune polyendocrine syndrome [96] . Additionally, the onset of disease can be modified by age [97] , sex [26] , epigenetic modifications [98] , lifestyle [99] , and environmental factors [100] . HPAH and IPAH generally have similar clinical courses, although there are some subtle but important differences. BMPR2 mutation carriers are younger at diagnosis and have worse haemodynamic parameters [17] . Both children and adults with PAH and BMPR2 mutations are less likely to respond to vasodilators, and are unlikely to benefit from treatment with calcium channel blockade [17, 101] . Symptomatic HPAH patients carrying ACVRL1 mutations, most without HHT, have an earlier age of onset and more rapid disease progression than HPAH patients with BMPR2 mutations, despite responsiveness to vasodilators at the time of diagnosis [102] . In contrast, many (but not all) TBX4-related cases of PAH follow a more benign course than that of BMPR2 mutation carriers [22] .
Common variants increase the risk of PAH
The cause of most IPAH cases is currently unknown, but common variants have been hypothesized to contribute to disease risk. A large international genome-wide association study identified common variants in the gene encoding cerebellin 2 that were associated with HPAH and IPAH [103] .
Genetic testing for PAH
Clinical genetic testing is now available for BMPR2 or for panels of PAH-associated genes, including BMPR2, ACVRL1, ENG, SMAD4, SMAD9, CAV1, KCNA5, KCNK3, GDF2 (BMP9), and NOTCH3. Genetic testing is appropriate for patients with HPAH, IPAH, and paediatric PAH, and is widely used to stratify risk for relatives of PAH patients. Genetic testing can be performed with targeted sequencing together with some form of gene dosage analysis, such as multiplex ligation-dependent probe amplification. Genetic counselling should be offered for predictive testing to review the complexities associated with genes with moderate penetrance and without currently available preventive measures [104] . For at-risk family members, patient education to ensure awareness of disease symptoms and disease surveillance by echocardiogram every 3 years should enable early diagnosis and treatment, which may improve outcomes.
Conclusion
The genetics of pulmonary hypertension are complex, owing to the genetic heterogeneity, incomplete penetrance, and sexual dimorphism in adults. There are likely to be additional genes and genetic and environmental modifiers for PAH still to be identified. Furthermore, the genes involved may differ between children and adults with PAH. Larger genetic studies, including epidemiological data and hormonal levels, will be necessary to tease apart these complexities.
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